Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 19/20 | 0.75 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15603144 | 0.88 | PIK3CA (0.57) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL20458875 | 0.87 | PIK3CA (0.57) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL15603003 | 0.86 | PIK3R1 (0.60) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL5562537 | 0.86 | PIK3R1 (1.00) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL3725366 | 0.85 | PIK3CA (0.55) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL15602979 | 0.85 | PIK3R1 (0.66) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL15602991 | 0.79 | PIK3R1 (0.73) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL15602986 | 0.77 | PIK3R1 (0.77) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL15603091 | 0.77 | PIK3R1 (0.72) | PIK3R1PIK3CAPIK3CDKCNH2PIK3CB | |
| SCHEMBL15603031 | 0.77 | PIK3R1 (0.82) | PIK3R1PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629771-B1 | USE OF PI3K INHIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2018-08-08 | — | — | EP | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| WO-2012052730-A1 | USE OF PI3K INIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| EP-2444084-A1 | Use of PI3K inibitors for the treatment of obesity | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | PIK3R1 6/4885PIK3CA 2/4885PIK3CD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.